SOCRA - Society of Clinical Research Associates Audits, Monitoring, and Inspections Questions and Answers 1

Question 1

Which of the following best describes the primary purpose of a sponsor-initiated quality assurance audit of a clinical trial site?

Accepted Answer

To provide a systematic and independent examination of trial-related activities and documents to determine compliance with the protocol, GCP, and regulatory requirements.

Answer

A quality assurance audit is a formal, independent evaluation to ensure compliance and data integrity. [3, 4] It is distinct from monitoring (which may involve extensive source data verification), site training, or regulatory reporting, which are separate functions. [3]

Question 2

A clinical research site receives notification from the FDA of a forthcoming 'for-cause' inspection. This type of inspection is most likely triggered by what?

Accepted Answer

A specific concern, such as a complaint, unusual pattern of adverse events, or evidence of significant non-compliance.

Answer

A 'for-cause' inspection is initiated in response to specific concerns or reports that raise questions about the conduct of the study at a site. [2, 7, 10] Routine or pre-approval inspections are not classified as 'for-cause'.

Question 3

During a routine on-site monitoring visit, a Clinical Research Associate (CRA) is responsible for all of the following activities EXCEPT:

Accepted Answer

Issuing an official FDA Form 483 for observed regulatory non-compliance.

Answer

Issuing a Form FDA 483, which lists inspectional observations, is a function reserved for an FDA inspector at the conclusion of a regulatory inspection. [16, 20] A CRA's role is to identify and help correct issues, but they do not have the regulatory authority to issue this form.

Question 4

An FDA inspector concludes an inspection of a clinical site and issues a Form FDA 483 with three observations. What is the most critical next step for the Principal Investigator?

Accepted Answer

Submit a formal written response to the FDA, typically within 15 business days, detailing a corrective and preventive action (CAPA) plan.

Answer

Upon receiving a Form FDA 483, the investigator is expected to provide a timely written response to the FDA, generally within 15 business days. [18, 22] This response should address each observation and outline the site's plan for corrective and preventive actions. [18]

Question 5

A sponsor is implementing a risk-based monitoring approach for a large, multi-center trial. Which of the following best characterizes this strategy?

Accepted Answer

Focusing monitoring efforts on critical data and processes, with the intensity and frequency of monitoring tailored to sites identified as having higher risk.

Answer

Risk-based monitoring (RBM), as encouraged by ICH E6(R2), involves identifying and prioritizing risks to critical trial processes and data, then focusing monitoring activities on those areas of highest risk. [28, 19] It does not necessarily eliminate on-site visits but tailors the monitoring strategy based on risk factors. [19, 28]

(SOCRA) Society of Clinical Research Associates Practice Test

(SOCRA) Society of Clinical Research Associates Practice Test

SOCRA - Society of Clinical Research Associates Audits, Monitoring, and Inspections Questions and Answers 1